BECAS
PRADA Jesica Giselle
congresos y reuniones científicas
Título:
ANGIOTENSIN II, K AND CHEMOTHERAPEUTIC DRUGS INCREASE CELL RESISTANCE VIA ACSL4 AND ABCG2 IN ADRENOCORTICAL CARCINOMA
Autor/es:
RIOS MEDRANO M; PRADA J; MALOBERTI P; CASTILLO A; PODESTA E; ORLANDO U
Lugar:
Ciudad de Salta
Reunión:
Congreso; Reunión anual conjunta de las sociedades SAIB- PABMB 2019; 2019
Institución organizadora:
SAIB- PABMB
Resumen:
Acyl CoA synthetase 4 (ACSL4) is an enzyme that regulates steroidogenesis in physiological conditions. However, in pathological scenarios, anincrease in ACSL4 expression is associated with the promotion of a highly aggressive cell phenotype in breast, prostate, colon, and liver cancer.ATP-binding cassette (ABC) transporters are transmembrane proteins that use energy through ATP hydrolysis to translocate low-weight molecules.Whereas in physiological conditions these transporters are in charge of maintaining homeostasis in different tissues, for example through steroidefflux, their participation in pathological events is associated with drug resistance, for example through chemotherapeutic drug efflux. Our grouphas previously reported the involvement of ACSL4 in steroidogenesis and breast cancer chemotherapy resistance, partly mediated by the regulationof the ABCG2 transporter. In this context and given that adrenocortical cells generate both steroids and highly aggressive tumors such asadrenocortical carcinoma, we used NCI-H295R, a cell line developed from a human adrenocortical tumor, as a steroidogenic and carcinogenicmodel to study the participation of ACSL4 and ABCG2 in chemotherapeutic drug resistance. Short-term treatment with angiotensin II or Kincreased ACSL4 expression and ABCG2 mRNA expression and protein levels. This treatment increased fluorescent compound efflux from cells.Inhibition assays further proved that compound efflux was mediated by ABCG2. Moreover, the continuous chemotherapeutic treatment alsorendered an increase in ACSL4 and ABCG2 expression and drug efflux from cells. In addition, both pre-treatment with angiotensin II or K followedby high-concentration chemotherapeutic treatment and continuously increasing chemotherapeutic treatment induced an increase in cell survivalrates as compared to non-stimulated non-treated cells. Altogether, these results suggest the participation of ACSL4 and ABCG2 in the mechanismsunderlying adrenocortical carcinoma cell resistance to chemotherapy and hint at ACSL4 as a potential therapeutic target in this type of tumor toinhibit steroid synthesis, resistance to treatment and tumor growth.